Immediate Release Opioid Analgesics (Brand and Generic): Acute Pain Duration Limit with MME Limit and Post Limit Policy
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Iowa Policy 05.02.38 alerts
Get alerted when Policy 05.02.38 changes without checking for updates manually.
Monitor payer policy activity
Defines covered indications and limitations for immediate-release opioid analgesics (brand and generic) for acute pain and describes FDA-approved indications and limitations of use for specific products; applies to Wellmark/Blue Cross Blue Shield - Iowa benefit determinations and providers prescribing these agents.
No material clinical or coverage changes in this revision.
Coverage criteria for immediate-release opioid analgesics
General coverage criteria for immediate-release opioids
Covered when ALL of the following are met
General coverage
- Alternatives considered: Alternative treatment options (e.g., nonopioid analgesics or opioid combination products) have not been tolerated or have not provided adequate analgesia.
Repeated limitation-of-use language
See product Limitations of Use (e.g., codeine, morphine, hydromorphone)
Coverage with prior authorization
Covered when ONE of the following is met (OR/AND logic as shown):
Lowest effective dosage for opioid‑naïve patients; chronic pain generally >3 months.
Quantity limits may apply.
Initial vs Post Limit Application
Coverage and quantity limit application depend on recent cancer/SCD/palliative care status and recent opioid prescription history:
See next nodes for branching by prior opioid exposure.
Column A/B define product-specific initial/post limits in the chart.
If incoming prescription is ≤7 days, initial quantity limits apply.
Initial and post-limit coverage criteria
Covered when ALL of the following are met for patients without cancer, sickle cell disease, palliative, or hospice indicators:
chunk 55
chunk 55
chunk 60
Exceptions to acute pain limits
Not subject to acute pain duration limits and post limit quantities when ANY of the following apply:
chunk 54
chunk 54
chunk 54
chunk 54
chunk 54
Meperidine hydrochloride oral solution and tablets are indicated for management of acute pain when alternatives are inadequate, but meperidine should not be used for treatment of chronic pain due to risk of accumulation of the metabolite normeperidine and resultant toxicity (e.g., seizures).
Claims history or a prescription claim diagnosis indicating cancer, sickle cell disease (SCD), palliative care, or hospice within the specified lookback period exempts the patient from the policy’s acute pain duration and quantity limits; documentation of these diagnoses or relevant drug claims in the past 365 days will remove the acute-limit restrictions.
Drugs and prescription claims that meet the cancer, sickle cell disease, palliative care, or hospice criteria will be routed to and paid under the CVS Caremark-administered prescription benefit rather than subject to the standard initial/post quantity limits described in this policy.
Use of meperidine as first-line oral therapy is discouraged because oral administration increases formation of normeperidine via first-pass metabolism; meperidine should be limited to short-term use only. Accordingly, the policy sets specific supply limits for meperidine with an initial quantity corresponding to a 72‑hour supply and a post limit corresponding to a 96‑hour supply to discourage chronic or first-line use.
Pentazocine (including pentazocine/naloxone) is not commonly used because of dysphoric reactions and short duration of action; given limited usefulness and safety concerns, the policy sets the one‑month and three‑month limits the same for pentazocine formulations.
Clinical evidence is limited for benefit of long‑term opioid therapy for chronic pain and harms increase with higher doses. The policy notes that improvements in pain are generally small and may diminish over time, and that risks are dose dependent, supporting restricted duration and dose-based limits for chronic opioid therapy.
Conservative therapy and trial requirements before opioid use
Alternatives must have been tried and found inadequate or not tolerated before reserving opioid therapy.
Policy repeatedly states reserve opioids when alternatives are inadequate or not tolerated.
Trial of non-opioid options recommended prior to IR opioid use when feasible.
From clinical rationale and stepwise use guidance.
trial or intolerance of alternatives — documentation of trial or intolerance required as part of conservative treatment requirements
Policy requires alternatives be not tolerated or inadequate before opioid use.
Coding, thresholds, and exemption lookback definitions
| No codes listed |
Provider actions, prior authorization, and documentation requirements
Verify benefits and contract applicability
Verify member benefits and contract applicability at the time of service; this policy may not apply to all benefit designs (e.g., FEP) and exclusions, limitations, or exceptions may affect coverage determinations.
Obtain PA for quantities above initial and post limits
Submit prior authorization for opioid quantities that exceed the initial quantity limits (initial limits correspond to monthly quantities ≤ 90 MME/day) or for post‑limit quantities (monthly quantities set not to exceed 200 MME/day); the system will reject requests that exceed these limits and indicate that PA is required.
PA required for initial fills >7 days in opioid‑naïve patients
For opioid‑naïve patients, do not request an initial fill for more than a 7‑day supply without prior authorization; if an initial fill >7 days is submitted without PA and there is no opioid claim in the prior 90 days, the claim will reject and only a 7‑day supply may be dispensed without PA.
PA required when prescriptions exceed established quantity limits
If an opioid prescription exceeds either the applicable initial quantity limit (per the Opioid Analgesics IR Quantity Limits Chart) or the post‑limit monthly quantity corresponding to 200 MME/day, submit a prior authorization; claims exceeding these limits will reject with PA required.
Reserve specified opioid products when alternatives inadequate
Reserve the listed immediate‑release opioid products for patients only when alternative treatments (for example, non‑opioid analgesics or opioid combination products) have not been tolerated or have not provided adequate analgesia.
Reserve specific opioid agents (e.g., RoxyBond, tramadol) for limited use
Reserve certain opioid products (e.g., RoxyBond, tramadol formulations) for use only when non‑opioid analgesics or opioid combination products are not tolerated or are ineffective; document prior trial or intolerance of alternatives.
Use IR opioids stepwise after non‑opioid options tried
Prescribe immediate‑release opioids only after non‑opioid analgesics or opioid combination products have been tried and either were not tolerated or did not provide adequate analgesia; document the trial or intolerance in the medical record.
Step from non‑opioid therapy before IR opioid initiation
Reserve immediate‑release opioids for patients who have failed or not tolerated alternative treatments (non‑opioid analgesics or opioid combination products) before initiating IR opioid therapy; maintain documentation of prior therapies.
Verify individual member benefits at time of service
Verify individual member benefits and contract language at the time of service and confirm there are no contract exclusions before determining medical necessity or submitting prior authorization requests.
Provide documentation for exemption from acute limits
Document evidence to exempt the patient from acute‑pain duration and post‑limit quantity limits: claims or medical record documentation indicating cancer, sickle cell disease, hospice, or palliative care within the past 365 days (or a hospice patient residence code on the prescription claim).
Document diagnosis and prescription history (ICD‑10 / claims)
Include in the claims record or member health profile relevant ICD‑10 diagnosis codes or prescription claims: cancer, sickle cell disease, or palliative care within the past 365 days to route payment under the prescription benefit and exempt from acute duration and quantity limits.
Evidence required for cancer/SCD/palliative/hospice exemption
Provide documentation or claims evidence of prior diagnosis or treatment for cancer, sickle cell disease, palliative care, or hospice (including relevant prescription fills or ICD‑10 codes) to qualify for exemption from acute pain limits and have the claim paid under the prescription benefit administered by CVS Caremark.
Confirm benefits, exclusions, limitations, or exceptions may apply
Confirm whether benefit designs, exclusions, limitations, or exceptions apply (this policy may not apply to FEP); verify individual member benefits before assuming policy rules govern coverage.
First‑fill >7 days will reject without PA or limit to 7 days
If submitting a first opioid fill that exceeds a 7‑day supply, expect the claim to reject; prescriber must either limit the dispensed supply to 7 days or submit a prior authorization for additional quantity.
Claims reject when exceeding 7 days in a 90‑day period without PA
When a patient exceeds 7 days of opioid therapy for the first time in a 90‑day period, the claim will reject and prior authorization is required for additional quantities.
Initial fill >7 days for opioid‑naïve patients will reject without PA
If a patient has no opioid fill in the prior 90 days and an initial opioid prescription is for more than a 7‑day supply submitted without PA, the claim will reject and the patient can only receive a 7‑day supply without prior authorization.
Initial opioid prescriptions >7 days reject for opioid‑naïve patients
Claims for initial opioid prescriptions exceeding a 7‑day supply for patients without an opioid fill in the prior 90 days will reject; the patient may receive up to a 7‑day supply or the prescriber must submit a prior authorization for additional quantity.
Exceeding initial or post‑limit quantities will trigger PA requirement
Requests that exceed the initial quantity limit (per the Opioid Analgesics IR Quantity Limits Chart) or post‑limit quantities (capped to a monthly quantity corresponding to 200 MME/day) will reject with a message that prior authorization is required.
Background and policy scope
Immediate‑release opioid analgesics are intended for management of acute pain severe enough to require an opioid when alternative treatments are inadequate. The policy emphasizes reserving these agents for patients who have not tolerated or not achieved adequate analgesia from nonopioid therapies or opioid combination products. Acute pain is defined per CDC guidance as typically lasting <1 month, and coverage for acute indications is limited in duration to 1 month; chronic pain coverage, when criteria are met, is limited to 6 months because evidence of long‑term benefit is insufficient and harms are dose dependent.
Definitions and term clarifications
Policy revision history
Policy reviewed and revised; current effective date set to 2026-06-13.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.